Table 2 Distribution of the different tumor entities in the complete cohort (n = 438)
Tumor entities | n | % |
|---|---|---|
gynecological cancer | 74 | 16.9 |
breast | 44 | 10.0 |
cervix uteri | 10 | 2.3 |
ovary | 10 | 2.3 |
DCIS | 6 | 1.4 |
corpus uteri | 4 | 0.9 |
head and neck | 42 | 9.6 |
larynx | 16 | 3.7 |
oropharynx | 6 | 1.4 |
palate | 4 | 0.9 |
hypopharynx | 4 | 0.9 |
parotid gland | 4 | 0.9 |
other illdefined sites in the lip, oral cavity and pharynx | 2 | 0.5 |
nasopharynx | 2 | 0.5 |
floor of mouth | 2 | 0.5 |
accessory sinuses | 2 | 0.5 |
colorectal and anal cancer | 38 | 8.7 |
colon | 32 | 7.3 |
rectum | 4 | 0.9 |
anal | 2 | 0.5 |
urological cancer | 36 | 8.2 |
kidney (except renal pelvis) | 18 | 4.1 |
bladder | 16 | 3.7 |
renal pelvis | 2 | 0.9 |
thyroid gland | 30 | 6.8 |
non-melanoma skin cancer | 26 | 5.9 |
basal cell cancer | 20 | 4.6 |
squamous cell cancer | 4 | 0.9 |
Bowen disease | 2 | 0.5 |
lymphoma | 26 | 5.9 |
non-follicular lymphoma | 20 | 4.6 |
Hodgkin lymphoma | 4 | 0.9 |
other specified types of T−/NK-cell-lymphoma (C83) | 2 | 0.5 |
brain and spinal cord | 26 | 5.9 |
glioblastoma | 20 | 4.6 |
oligoastrozytoma | 2 | 0.5 |
oligodendroglioma | 2 | 0.5 |
ependymom | 2 | 0.5 |
male genital tract | 24 | 5.5 |
prostate | 20 | 4.6 |
testis | 4 | 0.9 |
pancreas | 20 | 4.6 |
adeno carcinoma | 16 | 3.7 |
NET | 4 | 0.9 |
leukemia | 16 | 3.7 |
AML | 10 | 2.3 |
CLL | 4 | 0.9 |
CML | 2 | 0.5 |
melanoma | 16 | 3.7 |
nodular | 6 | 1.4 |
superficial spreading | 6 | 1.4 |
acral lentiginous | 2 | 0.5 |
without further indication | 2 | 0.5 |
stomach | 14 | 3.2 |
adeno carcinoma | 12 | 2.7 |
NET | 2 | 0.5 |
multiple myeloma | 14 | 3.2 |
liver and biliary tracts | 12 | 2.7 |
bronchus and lung | 8 | 1.8 |
SCLC | 4 | 0.9 |
NSCLC | 2 | 0.5 |
NET | 2 | 0.5 |
sarcomas | 6 | 1.4 |
chondrosarcoma | 4 | 0.9 |
synovial sarcoma | 2 | 0.5 |
adrenal gland | 4 | 0.9 |
esophagus | 2 | 0.5 |
CUPs | 2 | 0.5 |
Kaposi sarcoma | 2 | 0.5 |
Total | 438 | 100 |